ArticleACS chemical biology2015
A Phenotypic Screen for Functional Mutants of Human Adenosine Deaminase Acting on RNA 1.
Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Target-stabilized base editors enable robust high-fidelity RNA editing.Nature communications · 2026Article
- RNA editing in Parkinson's disease: emerging mechanisms, translational potential, and current challenges.Frontiers in neuroscience · 2026Review
- ADARs: pleiotropy in function, versatility in application.Nucleic acids research · 2025Review
- Biochemical profiling and structural basis of ADAR1-mediated RNA editing.Molecular cell · 2025Article
- Rational design of base, sugar and backbone modifications improves ADAR-mediated RNA editing.Nucleic acids research · 2024Article
- Nuclear aggregates of NONO/SFPQ and A-to-I-edited RNA in Parkinson's disease and dementia with Lewy bodies.Neuron · 2024Article
- A pipeline for identifying guide RNA sequences that promote RNA editing of nonsense mutations that cause inherited retinal diseases.Molecular therapy. Nucleic acids · 2024Article
- Engineered deaminases as a key component of DNA and RNA editing tools.Molecular therapy. Nucleic acids · 2023Review
- Chemical Modifications in RNA: Elucidating the Chemistry of dsRNA-Specific Adenosine Deaminases (ADARs).Accounts of chemical research · 2023Article
- Identification of exceptionally potent adenosine deaminases RNA editors from high body temperature organisms.PLoS genetics · 2023Article
- Rational Design of RNA Editing Guide Strands: Cytidine Analogs at the Orphan Position.Journal of the American Chemical Society · 2021Article
- Regulation of RNA editing by intracellular acidification.Nucleic acids research · 2021Article
- Base editing: advances and therapeutic opportunities.Nature reviews. Drug discovery · 2020Review
- RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences.International journal of molecular sciences · 2020Review
- RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells.Nucleic acids research · 2019Article
- Selective Recognition of RNA Substrates by ADAR Deaminase Domains.Biochemistry · 2018Article
- Mechanistic implications of enhanced editing by a HyperTRIBE RNA-binding protein.RNA (New York, N.Y.) · 2018Article
- RNA editing with CRISPR-Cas13.Science (New York, N.Y.) · 2017Article
- DNA editing in DNA/RNA hybrids by adenosine deaminases that act on RNA.Nucleic acids research · 2017Article
- Probing RNA recognition by human ADAR2 using a high-throughput mutagenesis method.Nucleic acids research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Adenosine deaminases acting on RNA (ADARs) are RNA-editing enzymes responsible for the conversion of adenosine to inosine at specific locations in cellular RNAs. ADAR1 and ADAR2 are two members of the family that have been shown to be catalytically active. Earlier, we reported a phenotypic screen for the study of human ADAR2 using budding yeast S. cerevisiae as the host system. While this screen has been successfully applied to the study of ADAR2, it failed with ADAR1. Here, we report a new reporter that uses a novel editing substrate and is suitable for the study of ADAR1. We screened plasmid libraries with randomized codons for two important residues in human ADAR1 (G1007 and E1008). The screening results combined with in vitro deamination assays led to the identification of mutants that are more active than the wild type protein. Furthermore, a screen of the ADAR1 E1008X library with a reporter construct bearing an A•G mismatch at the editing site suggests one role for the residue at position 1008 is to sense the identity of the base pairing partner for the editing site adenosine. This work has provided a starting point for future in vitro evolution studies of ADAR1 and led to new insight into ADAR's editing site selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.